The BeiGene approach
Over the past 13 years, BeiGene has redesigned how medicines are discovered and developed, from research and clinical development through to manufacturing and commercial operations.
BeiGene’s patient-centric philosophy is core to providing wide and rapid access to affordable, life-changing medicines globally, regardless of socioeconomic status. Our strategy means taking innovative approaches to clinical trials, enabling pricing and reimbursement flexibility within each market.
The BeiGene approach to developing medicines is distinct in the pharmaceutical/biotech industry, ensuring that patients’ needs are prioritised at every step, bringing maximal positive impact.
World-class innovation
We have a team of 950 world-class scientists dedicated to discovering new cancer medicines – one of the largest oncology research teams in the industry. Together we are committed to developing the best, first-in-class clinical candidates.
Cost-effective, innovative approach for rapid patient access
Our innovative approach to clinical trials provides an opportunity to develop new medicines faster and more cost-effectively than conventional human clinical trials. Such approaches include:
- Using our in-house capabilities to deliver global clinical trials faster and more affordably than previously possible. Our China-based clinical centres provide a substantial patient pool, with a high rate of interest in trial participation, which contributes significantly to our global trials.
- Recognising that head-to-head clinical trials have the greatest impact on existing treatment management.
- Managing our trials internally, thus increasing the speed of patient enrolment and reducing clinical trial costs by 30% compared with industry standards.
- Collaborating directly with healthcare professionals and regulatory health authorities to facilitate more efficient approvals of medicines.
By acting quickly, and at a lower cost than conventional approaches, we benefit payers and healthcare professionals. This means we can better support patients in the UK, Ireland and globally through accelerated delivery and access to new treatments.
Our collaborative and flexible approach to pricing and reimbursement requirements of each market has also resulted in rapid patient access, often faster than industry averages.
Broad access for patients who need it the most
We are pursuing widespread registration in developed and developing markets simultaneously to drive broader patient access to life-changing cancer medicines, regardless of patients’ socioeconomic status.
- Our global clinical trials include participants from over 45 countries and regions to ensure our studies can be used in regulatory filings across markets.
We are also committed to radically improving access for patients with the greatest need.